IQVIA Holdings Inc. $IQV Shares Sold by Capital Research Global Investors

Key Points

• Capital Research Global Investors cut its stake by 50.2% in IQVIA during Q3, selling 908,395 shares and retaining 901,348 shares worth about $171.1 million.
• Several other large institutions (AllianceBernstein, Artisan, JPMorgan, Nordea, Cantillon) increased their positions while overall institutional ownership remains high at 89.62%.
• Analysts are broadly positive—IQVIA has an average rating of "Buy" with an average price target of $229.13; the company slightly beat Q earnings (EPS $3.42 vs. $3.40), reported revenue up 10.3%, and set FY2026 guidance of 12.55–12.85 EPS, while the stock trades around $171.64 (12‑month range $134.65–$247.04).

Capital Research Global Investors lowered its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 50.2% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 901,348 shares of the medical research company's stock after selling 908,395 shares during the quarter. Capital Research Global Investors owned approximately 0.53% of IQVIA worth $171,132,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Alliancebernstein L.P. lifted its position in shares of IQVIA by 0.6% in the second quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company's stock valued at $560,379,000 after acquiring an additional 19,573 shares in the last quarter. Artisan Partners Limited Partnership raised its stake in IQVIA by 4.9% in the 3rd quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company's stock valued at $652,246,000 after purchasing an additional 161,085 shares during the last quarter. JPMorgan Chase & Co. raised its stake in IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company's stock valued at $492,659,000 after purchasing an additional 581,157 shares during the last quarter. Nordea Investment Management AB lifted its holdings in IQVIA by 12.3% in the 3rd quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company's stock valued at $421,257,000 after purchasing an additional 253,759 shares in the last quarter. Finally, Cantillon Capital Management LLC boosted its stake in shares of IQVIA by 27.3% during the 3rd quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company's stock worth $366,002,000 after purchasing an additional 413,256 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on IQV shares. Weiss Ratings reissued a "hold (c)" rating on shares of IQVIA in a research report on Thursday, January 22nd. Evercore reaffirmed an "outperform" rating and issued a $225.00 target price on shares of IQVIA in a research note on Thursday, February 5th. Morgan Stanley set a $240.00 price target on IQVIA in a report on Wednesday, February 11th. Truist Financial reduced their price target on IQVIA from $290.00 to $245.00 and set a "buy" rating on the stock in a research note on Thursday, February 19th. Finally, Wall Street Zen raised IQVIA from a "hold" rating to a "buy" rating in a research report on Saturday, February 21st. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, IQVIA presently has an average rating of "Buy" and an average price target of $229.13.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $171.64 on Thursday. The business has a 50-day moving average of $204.05 and a two-hundred day moving average of $207.14. The firm has a market capitalization of $29.13 billion, a PE ratio of 21.84, a P/E/G ratio of 1.65 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same period in the previous year, the company posted $3.12 EPS. The company's revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.